INTRODUCTION
Arterial stiffness (AS) is a marker of subclinical vascular disease that has been documented among young patients with type 1 diabetes (1). The early development of AS in these patients may be a consequence of the exposure of blood vessels to the chronic detrimental effects of hyperglycemia.
Peripheral AS results from medial arterial calcification (MAC), which is a complex dynamic process modified by a variety of molecular signaling pathways (2) . Although peripheral AS has been linked to peripheral arterial disease (PAD) (3), the impact of MAC on peripheral vascular beds is poorly understood even though advanced stages, characterized by loss of elasticity of arterial walls, are associated with worse tissue perfusion ending in arterial flow stasis (4). In the past, MAC was considered a benign condition, even though concomitant PAD was present in a significant subset of patients, at least in those with type 1 diabetes (5). Nowadays, arterial wall stiffness is recognized as a key risk factor for cardiovascular morbidity and mortality and is strong independent predictor of future cardiovascular events and all-cause mortality (6).
Cardiovascular autonomic neuropathy (CAN) is another common, yet often underdiagnosed, complication of type 1 diabetes (7,8) that may lead to severe morbidity and mortality. Albeit not fully understood from a pathophysiological point of view, CAN may results in a wide spectrum of clinical manifestations, from resting tachycardia to structural cardiomyopathy (9). An early indicator of CAN is the reduced heart rate (HR) variability derived both from the loss of parasympathetic regulation and from sympathetic override (9). Such an imbalance may be easily detected at the clinical setting, permitting an early diagnosis of CAN at subclinical stages (10).
The relationship between CAN and atherosclerosis is well-known (11-13). The autonomic nervous system regulates HR and vascular tone and its dysfunction may contribute to the development of atherosclerosis and AS in patients with diabetes mellitus (8). The SEARCH Cardiovascular Disease study (7) suggested that even young patients with type 1 diabetes may present with signs of early autonomic dysfunction. Likewise, CAN and AS has been related independently of the presence of other classic cardiovascular risk factors in these subjects (8). However, whether or not the presence of CAN is associated to concomitant asymptomatic PAD (aPAD) in patients diagnosed of AS, has not been elucidated so far.
We hypothesize that CAN may be associated with both peripheral AS -as defined by an ankle branchial index (ABI) > 1.2 -and with the concomitant occurrence of aPAD. With this hypothesis in mind, our study explored the cardiovascular autonomic function of patients with type 1 diabetes with or without AS, by using methods that can be easily implemented in routine clinical practice, in order to clarify the putative role that CAN may play in the development of aPAD in patients with type 1 diabetes and presenting with AS.
METHODS

Study Population
The present preplanned study is part of a larger clinical trial (ClinicalTrials.gov Identifier: NCT02910271) designed to address the prevalence and clinical features of the asymptomatic peripheral atherosclerotic profile of patients with type 1 diabetes (5).
A detailed description of this trial has been reported elsewhere (5). In short, inclusion criteria included: diagnosis of type 1 diabetes before the age of 30 (14), supported by i) presence of circulating islet-specific pancreatic autoantibodies against the 40K fragment of tyrosine phosphatase, glutamic acid decarboxylase, and/or insulin at diagnosis or during the course of disease, and/or ii) presence of diabetic ketoacidosis at diagnosis, and iii) an absolute requirement for intensive insulin replacement therapy because of permanent (15) ; ii) previous diagnosis of PAD; iii) renal transplantation or renal replacement therapy; iv) previous diagnosis of cerebrovascular disease; v) ongoing pregnancy; and vi) other types of diabetes mellitus. Two-hundred seventy-two adults (≥ 18 year-old) patients with type 1 diabetes, out of 401 consecutive patients attending at our Diabetes Unit, matched these criteria and entered the study, even though only the data from 264 were finally analyzed for technical reasons ( Figure  1 ). The study protocol conformed to the ethical guidelines of the Declaration of Helsinki as revised in 2008, and was approved by the local ethics committee (Date of approval: January 22, 2016; Protocol ID: 464/15). Informed consent was obtained from all individual participants included in the study.
Anthropometric, biochemical, and clinical variables
The medical records of the patients were reviewed for their past medical history and current medications including clinical parameters related to type1 diabetes. Patients were also asked about their current smoking status.
Study subjects were submitted to a complete anthropometric evaluation, and classified according to their body mass index (BMI). Renal function, serum lipid profiles, HbA 1c concentrations, and proinflammatory profiles were also assayed.
All patients were assessed for diabetic peripheral neuropathy (16) by means of a detailed clinical history, clinical tests for large-fiber function, protective sensation and detection of feet at risk for ulceration by a 128-Hz tuning fork for vibration perception, ankle reflexes, and a 10-g monofilament test.
Assessment of peripheral vascular disease
The patients were examined for signs of chronic circulatory insufficiency in their lower extremities, and their dorsalis pedis and tibialis posterior pulses were also categorized as present, weak or absent. Peripheral AS was assessed non-invasively by measuring bilateral ABI using a Minidop ES 8 Mhz sonographic device (Hadeco, Inc., Miyamae-ku Kawasaki, Japan). ABI was calculated by dividing the systolic blood pressure (BP) measurement obtained at the tibialis posterior and dorsalis pedis arteries of left and right ankles by the highest of the systolic BP measurements obtained at the left and right brachial artery (17), and was categorized as normal (ABI = 0.91 -1.20), reduced (ABI ≤ 0.90), or increased (ABI > 1.20). The latter was assumed to be an equivalent of AS.
Seventeen patients showing reduced ABI were submitted to the Department of Vascular Surgery for full assessment of peripheral atherosclerotic disease and were excluded from the present study (Figure 1) . In all patients with increased ABI, the presence of aPAD was subsequently investigated by using a combination of the toe-brachial index (TBI) and peripheral artery Doppler ultrasound examination. TBI tests were performed by a plethysmographic detection device (Falcon Pro model, Viasonix S.A. Ra'anana, Israel). Waveform analyses from femoral, popliteal, anterior and posterior tibial, peroneal and pedial artery territories were performed, focusing on arterial diameter reduction as described earlier (18). A Toshiba Nemio Model SSA-550A Basic Diagnostic Ultrasound System (Toshiba Medical Systems S.A., Alcobendas, Madrid, Spain) with a 7.5 MHz probe served for peripheral artery Doppler ultrasound assessments. Waveform was categorized as normal (triphasic waveform) or abnormal (biphasic, monophasic or absent) (18). The diagnosis of PAD was defined by a TBI < 0.7 (19) and loss of the triphasic waveform pattern, visualization of atherosclerotic plaques, or PAD diagnostic criteria in arterial Doppler ultrasound examination (18). We used a modification of the Ewing Score (10) to diagnose the presence of CAN, which scored the responses of HR variability to deep breathing, standing, and to the Valsalva's maneuver, and the response of BP to active standing, as normal (0 points), borderline (0.5 points), or positive (1 point). A composite score ≥ 1 was diagnostic of CAN. For descriptive purposes, CAN was classified as early or mild when the Ewing score was between 1 and 2, and definitive when ≥ 2 (10). In patients showing two or more abnormal of HR variability tests and an abnormal blood BP test, CAN was considered severe (10). HR variability was measured between 7:00 and 9:00 a.m. in all participants after resting at supine position for 10 minutes, in a room maintained at stable temperature, using a Monitor OneDx ® System device (Qmed, Inc., New Jersey, USA). In brief, the HR response during respiration [Deep Breath (DB) test] was estimated by calculating the ratio of the maximum and minimum HR during six cycles of paced DB (E/I ratio). HR response to the Valsalva's maneuver (VAL test) was assessed by calculating the ratio of the longest R-R interval after the maneuver to the shortest interval during or shortly after the maneuver. HR response to standing [orthostatism (ORT) test] was calculated as the ratio of the longest R-R interval (found at about beat 30) to the shortest interval (found at about beat 15) after standing up (30:15 ratio).
Adrenergic innervation was assessed by the changes in BP and HR after 5 min of active standing with respect to the values recording during resting at supine. Systolic and diastolic BP at resting were measured three times, using an aneroid sphygmomanometer and stethoscope, while the subjects were seated for at least 5 min before a reading was taken (21). The average of the three measurements was used for estimation of office systolic and diastolic BP. Orthostatic hypotension was defined by a fall > 20 mmHg in systolic or > 10 mmHg in diastolic BP in response to standing (20) . The HR at resting was measured by palpating the radial pulse and counting the number of beats during 60 seconds. Resting tachycardia was defined by a HR > 100 beats per minute.
Both, vascular and autonomic function tests were conducted after an overnight fasting to avoid the possible interference of a postprandial surge in glucose levels (22). Early morning medications, including short-acting insulin, were withheld until the tests were completed. In addition, patients were advised to refrain from certain lifestyle activities immediately before the assessments, including exercise, smoking, and caffeine intake. Data were available for all BP tests, 99.6% of the E/I ratios, 95.5% the 30:15 ratios, and 97.3% of the Valsalva's tests. In 8 of 272 study subjects (2.9%) no data of any Ewing test were available for technical reasons, and these patients were excluded from final analyses ( Figure 1 ).
Sample size calculation
A sample size of 284 subjects was calculated for the primary objective of the clinical trial NCT02910271, which was determining the prevalence of aPAD in a population of subjects with type 1 diabetes attending our Diabetes Unit as already published (5). For the present study, we used the online sample size and power calculator provided by the Institut Municipal d'Investigació Mèdica from Barcelona, Spain, version 7.12 (https://www.imim.cat/ofertadeserveis/software-public/granmo/). Assuming a prevalence of CAN of 34%, as already published for French patients with type 1 diabetes presenting without symptomatic PAD (23), and setting alpha at 0.1 and beta at 0.2 for a one-sided test, the inclusion of at least 73 patients with type 1 diabetes and AS (cases) and 191 patients without AS (controls) would allow to recognize as statistically significant an odds ratio (OR) greater than 2 by a Poisson approximation.
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Statistical analysis
Data are shown as means ± SD, 95% CI [lower limit; upper limit], and counts (%) as appropriate. Normality of continuous variables was ensured by applying logarithmic and checked using the Kolmogorov-Smirnov test. We applied non-parametric tests to variables that did not follow the normal distribution even after transformation. Comparisons of discrete variables among study subgroups were performed using χ 2 or Fisher's exact tests, or logistic binary regression. Continuous variables were compared by t or Mann-Whitney U tests, and one-way ANOVA. Mean differences among groups were analyzed by post hoc Bonferroni's or Tamhane's T2 methods, as appropriate. We also calculated the OR and 95% CI for CAN of patients with AS and aPAD with respect to their counterparts showing normal ABI, using the Newcombe-Wilson method without continuity correction (24). Spearman's correlation analysis was used to evaluate the association between ABI values and the measurements of CAN. To perform the Spearman's correlation, we used the highest ABI result as done in earlier studies (25). Finally, multiple linear regression full-and stepwise-models (probability for entry ≤ 0.05, probability for removal ≥ 0.10) were performed to ascertain the main determinants of the variability in the tests of cardiovascular autonomic function. Besides the presence of AS and aPAD (both coded as no = 0, yes = 1), age, sex (coded as female = 0, male = 1), duration of diabetes, presence of microangiopathy (coded as no = 0, yes = 1), antiaggregant therapy (coded as absent = 0, present = 1), BMI, waist circumference, and systolic and diastolic BP were also introduced as independent variables. The level of statistical significance was set at a P value < 0.05.
RESULTS
Study population characteristics
The age of the patients at diagnosis of type 1 diabetes was 16 ± 8 year-old, whereas the mean age at inclusion was 35 ± 11 year-old. Mean duration of type 1 diabetes was 19 ± 10 years. All patients were under intensive insulin treatment (basal-bolus regimen) with 54 (21%) receiving continuous subcutaneous insulin infusion. Mean BMI was 25 ± 4 kg/m 2 . Thirty-five (13%) patients had hypertension and 72 (27%) had dyslipidemia. Mean HbA 1c of patients at inclusion was 7.5 ± 1.3%. Demographic and clinical characteristics of the participants are shown with detail in Table 1 .
In 73 (28% [23; 33]) patients an ABI > 1.2 suggested the presence of AS. These patients were older and had a longer duration of disease, as well as larger BMI, waist circumference and systolic BP values (Table 1) . Among patients with type 1 diabetes and peripheral AS, aPAD was found in 28 cases. Fifteen patients showed bilateral involvement, and only 2 subjects had bilateral non-complicated atherosclerotic plaques in the proximal femoral territories in arterial Doppler ultrasound assessment. No patients needed revascularization procedures.
Tests of cardiac autonomic function and prevalence of CAN
The prevalence of CAN was significantly greater in patients with AS compared with those showing normal ABI values (χ 2 : 15.6, P < 0.001) (Figure 2) , with the former being 3.1 times more likely to exhibit CAN than the latter (Figure 2) .
In the patients with normal ABI, CAN was categorized as early/mild in 41 (21.5%) cases, definitive in 3 (1.6%) cases, and severe in only one case. Among patients with AS, 32 (43.8%) subjects had an early/mild form of CAN, 3 (4.1%) had definitive CAN, whereas no patient presented with severe disease. Orthostatic hypotension was only present in two patients who also had AS. Finally, 4 (2.1%) with normal ABI and 3 (4.1%) with AS had resting tachycardia.
The subgroup of patients with type 1 diabetes showing the highest prevalence of CAN was comprised of those showing AS and aPAD concomitantly. The odds of having CAN was ADVANCE ARTICLE:
The
4.5 higher among them compared with patients showing normal ABI. However, the presence of AS without aPAD was also associated to higher odds of suffering from CAN ( Figure 1 ). Parasympathetic function outcomes, including the E/I ratio and 30:15 ratio (ORT test), were reduced in patients with AS compared to those showing normal ABI values (Table 2) . Nonetheless, the reduction in the 30:15 ratio was observed only in patients with concomitant aPAD (Table 2) . Regarding sympathetic function outcomes, the percentage of change in HR in response to active standing was also reduced in patients with AS (Table 2 ). In agreement, increasing ABI values correlated with decreasing HR variability, suggesting both sympathetic and parasympathetic dysautonomy (Figure 3 ).
Main determinants of cardiac autonomic function tests
In the linear regression models (Figure 4) , after evaluating the relative contributions of independent variables to the variability in the tests of cardiovascular autonomic function, the diagnosis of AS remained as a determinant of a reduced E/I ratio. Likewise, the presence of concomitant aPAD determined a reduced HR variability in response to orthostatism (30:15 ratio) after adjusting for other independent variables. Neither the presence of AS nor concomitant aPAD were significant determinants of other tests of cardiovascular autonomic function (data not shown).
DISCUSSION AND CONCLUSIONS
To our best knowledge, the present study is the first to evaluate the association between CAN and AS -defined by an ABI ≥ 1.2 -in patients with type 1 diabetes while screening for aPAD using a thorough assessment by vascular sonography. We hereby report that the compliance of peripheral arteries is related to cardiovascular autonomic dysfunction among young adults with type 1 diabetes who maintain an acceptable glycemic control. Our findings also show that the prevalence of CAN in patients with AS is 3-fold that of patients showing normal ABI values -with the highest prevalence in the subset of patients with both AS and concomitant aPAD -and that such an association persisted even after adjusting for the presence of other relevant cardiovascular risk factors and aPAD. Furthermore, in our cohort of patients with type 1 diabetes, peripheral AS appears to foster the association of cardiovascular autonomic dysautonomy and atherosclerosis, in what appears to be another link between CAN and cardiovascular morbidity.
This dual pathogenic pathway from cardiac autonomic dysfunction to AS and atherosclerosis is not only suggested by our findings, but is also supported by mounting evidence by others. Chronic hyperglycemia is associated to CAN and vascular disease in both type 2 and type 1 diabetes. In agreement, disorders in autonomic system modulation seem to precede the development of subclinical atherosclerosis -namely increase in carotid intima thickness -in patients with type 2 diabetes (26). Furthermore, indices of HR variability are reduced in patients with type 2 diabetes and PAD compared with their counterparts without peripheral disease measured by ABI (13), even though the positive predictive value for the diagnosis of PAD of this exploration, when not followed by any confirmatory test, is only around 50% (5). Also in type 2 diabetes, it has been reported that the cardiovascular autonomic response of patients with a reduced ABI is different compared to that of their counterparts showing increased ABI, suggesting that the autonomic nervous system, by regulating HR and vessel diameter, might contribute to both peripheral atherosclerosis and AS (27). Although it has been less studied than in patients with type 2 diabetes, the association between CAN and atherosclerosis has been reported in patients with type 1 diabetes too (12,28). Increased carotid intima thickness was recently related to CAN in individuals with type 1 diabetes (12). Furthermore, the combination of type 1 diabetes and CAN impacted negatively on carotid intima thickness even more than the sum of the ADVANCE ARTICLE: However, to our best knowledge, although those prior studies agree with our results, none of them considered the influence of aPAD on the association of CAN with peripheral AS as we did, despite AS and aPAD frequently coexisting in these patients (5).
What are the putative mechanisms linking cardioautonomic dysfunction, atherosclerosis and AS? The physiologic equilibrium of peripheral vascular beds and heart autonomic innervation is driven by complex interactions including metabolic processes such as oxidative stress and inflammation Khalaf, Jelinek, Robinson, Cornforth, Tarvainen, Al-Aubaidy (27), which are altered in patients with diabetes. Albeit CAN could lead to a pro-inflammatory state (28), other mechanisms such as BP dysregulation may also play a role on the development of AS and atherosclerosis (4). It is well-known that parasympathetic downregulation alters the physiologic fall in BP at night -the so-called non-dipping pattern -from early stages of CAN (32). The relative sympathetic overload and the exposition of the vascular bed to increased BP values during sleep in subjects with CAN may, at least in theory, promote vascular injury, AS and atherosclerosis.
In another way, a decrease in artery elasticity and autonomic dysfunction might develop together from early stages of type 1 diabetes (8,33), yet their order of appearance, and whether or not causality is involved in such association, are unsolved issues. Our present findings indicated an association between CAN and AS that was only explained in part by the coexistence of AS and aPAD. However, our cross-sectional design precludes any conclusion about causality. Theoretically, AS may contribute to cardiovascular dysautonomy by inducing baroreceptor dysfunction (4) and, conversely, CAN might favor AS by increasing HR since an increase in HR per se results in arterial stiffening independently of changes in the autonomic nervous system activity (34). But also, cardiovascular dysautonomy may impair the elasticity of the arterial wall by modulating the vascular tone of large vessels (35). However, instead of being causally related causality, CAN and AS may develop in parallel as a consequence of ageing in the presence of hyperglycemia. Hyperglycemia itself contributes to the atherosclerotic process by several mechanisms such as endothelial dysfunction and hypercoagulability (36). Chronic hyperglycemia promotes the accumulation of advanced glycation end products (AGEs) that perturb the adhesion properties of endothelial cells basement membrane and activate inflammatory cells in the vessel wall favoring the atherogenesis (36). Likewise, AGEs cause collagen cross-linking within the vascular wall leading to the loss of collagen elasticity (37), and subsequently, to the reduction in arterial and myocardial compliance (38).
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In any case, our study was not free of limitations. Our series of patients, by being composed almost entirely of Caucasian Spaniards, may not be representative of racially and ethnically diverse patients with type 1 diabetes. Also, being followed-up at a highlyspecialized Diabetes Unit, their glycemic control was possibly better than that of patients attending a general clinical practice, in whom the prevalence of AS and CAN might be even higher than that found in our study. Moreover, our study design also excluded subjects with severe microvascular and macrovascular complications, being vulnerable to survival bias. Lastly, we did not conduct one of the HR variability tests -the BP response to sustained hand-grip -of the Ewing score and vascular function was not explored thoroughly in the subset of patients with normal ABI results.
In conclusion, in our population of adult patients with type 1 diabetes, peripheral AS identified by ABI was associated with CAN, and this association occurred in a substantial proportion of cases independently of aPAD and other classic cardiovascular risk factors. Because both AS and CAN have been related to cardiovascular morbidity and mortality, the routine use of a non-invasive method such as the ABI may identify a subset of patients with undiagnosed CAN who may benefit from an early and aggressive management of cardiovascular risk factors. We cannot forget that the presence of CAN -often underdetected -is a mandatory diagnosis in all patients with diabetes mellitus (39), and carries a risk for cardiovascular events and silent ischemia even greater than smoking or LDL-cholesterol levels (40,41). Prospective studies targeting intensive management of cardiovascular risk factors in these patients are warranted.
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